Futura Medical

Futura Medical

Futura Medical (FUM) shares experienced a significant surge of 34.8% following the approval of over-the-counter sale (OTC) Marketing Authorisation for MED3000 by the US FDA. This positive development has propelled the company's stock to new heights.

The US FDA's decision to grant OTC Marketing Authorisation for MED3000 is a major milestone for Futura Medical. MED3000 is a topical gel developed by the company for the treatment of erectile dysfunction. With this approval, Futura Medical can now market and sell MED3000 directly to consumers without the need for a prescription.

This news has generated excitement among investors and industry experts alike. The approval of MED3000 for OTC sale opens up new opportunities for Futura Medical to reach a wider customer base and potentially increase its market share. The surge in the company's stock price reflects the positive sentiment surrounding this development.